Gris-Oliver, Albert http://orcid.org/0000-0003-1802-9541
Ibrahim, Yasir H.
Rivas, Martín A.
García-García, Celina
Sánchez-Guixé, Mònica
Ruiz-Pace, Fiorella
Viaplana, Cristina
Pérez-García, José M.
Llombart-Cussac, Antonio
Grueso, Judit
Parés, Mireia
Guzmán, Marta
Rodríguez, Olga
Anton, Pilar
Cozar, Patricia
Calvo, Maria Teresa
Bruna, Alejandra
Arribas, Joaquín
Caldas, Carlos http://orcid.org/0000-0003-3547-1489
Dienstmann, Rodrigo
Nuciforo, Paolo
Oliveira, Mafalda
Cortés, Javier http://orcid.org/0000-0001-7623-1583
Serra, Violeta http://orcid.org/0000-0001-6620-1065
Article History
Received: 3 July 2020
Revised: 18 January 2021
Accepted: 28 January 2021
First Online: 15 March 2021
Ethics approval and consent to participate
: Fresh tumour samples from patients with breast cancer were collected following an Institutional Research Board-approved protocol and the associated written informed consent. The study was compliant with the Declaration of Helsinki.Experiments were conducted following the European Union’s animal care directive (2010/63/EU) and were approved by the Ethical Committee of Animal Experimentation of the Vall d’Hebron Research Institute, the Catalan Government or by the National Research Ethics Service, Cambridgeshire (ref. <sup>35</sup> and ExternalRef removed).
: All data generated or analysed during this study are included in this published article [and its Supplementary information files].
: V.S. declares non-commercial research agreements with Genentech and Novartis. J.C. reports consulting for Roche, Celgene, Cellestia, AstraZeneca, Biothera Pharmaceutical, Merus, Seattle Genetics, Daiichi Sankyo, Erytech, Athenex, Polyphor, Lilly, Servier, Merck Sharp&Dohme, GSK, Leuko, Bioasis, Clovis Oncology and Boehringer Ingelheim; honoraria for Roche, Novartis, Celgene, Eisai, Pfizer, Samsung Bioepis, Lilly, Merck Sharp&Dohme and Daiichi Sankyo; research funding to the Institution: Roche, Ariad Pharmaceuticals, AstraZeneca, Baxalta GMBH/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffman-La Roche, Guardanth Health, Merck Sharp&Dohme, Pfizer, Piqur Therapeutics, Puma C and Queen Mary University of London; stock, patents and intellectual property of MedSIR; and travel, accommodation and other expenses for Roche, Novartis, Eisai, Pfizer and Daiichi Sankyo. M.O. declares research support from AstraZeneca, Genentech and Philips Healthcare; consultant role for Roche, GSK, PUMA Biotechnology and AstraZeneca; and has received honoraria from Roche. M.S.-G. is on the scientific advisory board of Menarini Ricerche and the Bioscience Institute, has received research funds from Puma Biotechnology, Daiichi-Sankio, Targimmune, Immunomedics and Menarini Ricerche, and is a cofounder of Medendi.org. C.C. is a member of AstraZeneca’s External Science Panel, of Illumina’s Scientific Advisory Board and is a recipient of research grants (administered by the University of Cambridge) from AstraZeneca, Genentech, Roche and Servier. R.D. is on advisory role of AstraZeneca, Roche and Boehringer-Ingelheim and has received speaker’s fees from Roche, Symphogen, IPSEN, Amgen, Servier, Sanofi and MSD; and research support from Merck. J.M.P.-G. reports an advisory role with Roche and Lilly. A.L.-C. has been a consultant for Roche, GlaxoSmithKline, Novartis, Celgene, Eisai and AstraZeneca in the previous 12 months and has stock options for Medica Scientia Innovation Research SL (MedSIR). All other authors declare no competing interests.
: We acknowledge the GHD-Pink programme, the FERO Foundation and the Orozco Family for supporting this study [to V.S.], as well as Fundación Mútua Madrileña [to J.C.]. This study has also been supported by the Catalan Agency AGAUR [2017 SGR 540 to V.S.]. V.S. is supported by the Miguel Servet Programme (ISCIII) [CPII19/00033]. A.G.-O. was awarded with a fellowship from the Agència de Gestió d’Ajuts Universitaris i de Recerca (FI-AGAUR, 2015 FI_B 01075), and M.S.-G. with a Marie Slodowska-Curie Innovative Training Networks (MSCA-ITN) Ph.D. fellowship (H2020-MSCA-ITN-2015_675392). The xenograft programme in the Caldas Laboratory was supported by Cancer Research UK and also received funding from an EU H2020 Network of Excellence (EuroCAN).